When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...

The MarketWatch News Department was not involved in the creation of this content. UCLA researchers found that routine PSMA PET/CT scans could help doctors select treatment approaches for the best long ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to ...